Clinical Trials Directory

Trials / Unknown

UnknownNCT01650766

Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers

Status
Unknown
Phase
Study type
Observational
Enrollment
80 (estimated)
Sponsor
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary purpose of the study is to investigate the correlation between the efficacy and toxicity of S-1 on gastric cancers and the expression of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyltransferase(OPRT).

Detailed description

TS, DPD and OPRT are the key enzymes on the metabolic pathway of 5-Fu. We will retrospectively analyze the clinicopathological features of the patients who have suffered an inoperative or recurrent gastric cancers and administrated with S-1, such as the overall survival (OS), progressive-free survival (PFS), Lauren's classification and toxicity of S1, etc. We will divide the patients into several subgroups according to the parameters above, and then investigate the correlation between the parameters and the expression of TS, DPD and OPRT. All of the analysis is retrospective, there is no different treatment operation once the subject enrolled in this study.

Conditions

Timeline

Start date
2012-02-01
Completion
2012-10-01
First posted
2012-07-26
Last updated
2012-07-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01650766. Inclusion in this directory is not an endorsement.

Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers (NCT01650766) · Clinical Trials Directory